Holo raises €1 million to bring personalised lab testing and daily-life health tracking to more users

November 14, 2025 at 03:04 PM UTC
EU-Startups
Original: EN
Holo raises €1 million to bring personalised lab testing and daily-life health tracking to more users

Barcelona-based health-tech startup Holo has secured €1 million in pre-Seed funding, aiming to revolutionize how individuals understand and manage their health. Holo’s platform integrates advanced lab testing, AI, and functional medicine, along with data from wearables like Apple Watch and Garmin. The funding, led by Calm/Storm Ventures and Mission VC, marks a step towards creating a comprehensive, user-friendly health management tool. The funding round saw participation from business angels and early customers, including individuals from companies like Magnific AI, Google, and Factorial. Holo's platform offers lab tests, wearable integration, and personalized medical reports. This approach aims to provide users with a dynamic health profile, analyzing over 110 biomarkers to offer insights into their well-being. This funding aligns with a broader trend of investment in the European preventive health sector, with other startups also securing significant funding. This includes companies like Aeon, Blue Longevity Clinic, Epigenica, Skleo Health, and MELP, indicating a growing interest in proactive health monitoring. The success of Holo, and other companies in this space, could lead to more personalized and accessible healthcare solutions. Holo, founded in 2024 by Francesc Navarro, Emilio Rodríguez, and Sergio Mosquera, is positioned to become a key player in the European health-tech landscape. The company aims to provide users with a comprehensive view of their health, promoting preventative measures and enhancing daily well-being. The vision is to empower individuals to take control of their health proactively.

To provide multilingual access, this article summary was automatically generated.

Source Information

Publication: EU-Startups
Published: November 14, 2025 at 03:04 PM UTC
All rights remain with the original publisher.